Abstract:Antidepressant drugs such as the serotonin (5-HT)/norepinephrine (NE) and dopamine (DA) reuptake inhibitors activate monoaminergic neurotransmission in various brain regions, such as the amygdala, the frontal cortex or the hippocampus. Although this property is well established, the post-synaptic mechanisms by which these pharmacological agents exert therapeutic activity in major depressive disorders (MDD) is not fully understood. Recent clinical and preclinical studies have indicated that the density and reactivity of glia and more particularly of astrocytes are reduced in MDD patients. These data along with the fact that astrocytes express monoaminergic transporters and receptors make these cells putative targets for antidepressant treatments. Accordingly, in vitro evidence has demonstrated that the application of various classes of antidepressant drugs on rodent primary astrocyte cultures elicits a wide spectrum of responses, from the rise in cytosolic calcium concentrations, as a marker of cellular activity, to the release of glucose metabolites, gliotransmitters and neurotrophic factors. Remarkably, antidepressant drugs also attenuate the release of inflammatory molecules from reactive astrocytes or microglia, suggesting that part of the beneficial effects in depressed patients or animal models of depression might result from the ability of antidepressants to regulate the synthesis and release of psychoactive substances acting on both pre- and post-synaptic neurons. Among the many long-term targets of antidepressant drugs, brainderived neurotrophic factor (BDNF) has been well studied because of the positive influence on adult hippocampal neurogenesis, synaptogenesis and the local serotonergic tone. This review will illustrate how the concept of the tripartite synapse, which is classically associated with different forms of plasticity involving glutamate, could be expanded to the monoaminergic systems to regulate antidepressant drug responses. The recent in vivo data supporting that hippocampal astrocytes act in concert with neurons to release BDNF under pharmacological conditions and thereby regulate different facets of anxiolytic-/antidepressant-like activities through neurogenesis-dependent and independent mechanisms will be emphasized.

Molecular Neurobiology and Promising New Treatment in Depression

Depression research: where are we now?

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

Breakthroughs and challenges for generating brain network-based biomarkers of treatment response in depression

Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections

The molecular neurobiology of depression

Neurobiological Investigation of Depression: Unraveling the Biological Basis of a Complex Mental Health Challenge

Molecular Biological Aspects of Depressive Disorders: A Modern View

The neurobiology of depression—revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms

5-HT2A mediated plasticity as a target in major depression: a narrative review connecting the dots from neurobiology to cognition and psychology

The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs

Assessing the Neuronal Serotonergic Target-based Antidepressant Stratagem: Impact of In Vivo Interaction Studies and Knockout Models

Optimizing Antidepressant Efficacy: Generalizable Multimodal Neuroimaging Biomarkers for Prediction of Treatment Response

Neuroanatomical, Biochemical, and Functional Modifications in Brain Induced by Treatment with Antidepressants

Serotonergic gene expression and depression: implications for developing novel antidepressants

New and emerging treatments for major depressive disorder

Neuroplasticity and the Biological Role of Brain Derived Neurotrophic Factor in the Pathophysiology and Management of Depression

Neurotrophic basis to the pathogenesis of depression and phytotherapy

Signaling pathways involved in antidepressant-induced cell proliferation and synaptic plasticity.

Potential Anti-Depressive Treatment Maneuvers from Bench to Bedside.